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Abstract
Preclinical testing of new therapeutic strategies in relevant animal models is an essential part of drug devel-
opment. The choice of animal models of disease that are used in these studies is driven by the strength of the
translational data for informing about safety, efficacy, and success or failure of human clinical trials. Hemo-
philia B is a monogenic, X-linked, inherited bleeding disorder that results from absent or dysfunctional co-
agulation factor IX (FIX). Regarding preclinical studies of adeno-associated virus (AAV)-mediated gene
therapy for hemophilia B, dogs with severe hemophilia B (<1% FIX) provide well-characterized phenotypes
and genotypes in which a species-specific transgene can be expressed in a mixed genetic background. Cor-
rection of the hemophilic coagulopathy by sustained expression of FIX, reduction of bleeding events, and a
comprehensive assessment of the humoral and cell-mediated immune responses to the expressed transgene and
recombinant AAV vector are all feasible end points in these dogs. This review compares the preclinical studies
of AAV vectors used to treat dogs with hemophilia B with the results obtained in subsequent human clinical
trials using muscle- and liver-based approaches.
Introduction
The successes of adeno-associated virus (AAV)-mediated gene therapy of hemophilia B in humans have
been welcome and exciting advances.1–6 Through detailed
studies of the relatively small number of people with he-
mophilia B successfully treated with gene therapy to date,
investigators have also identified barriers to more widespread
applicability of this approach including preexisting anti-
bodies to AAV, manufacturing challenges for large-scale
production of AAV vectors, and the need for long-term fol-
low-up to identify potential safety issues.7 This review fo-
cuses on the role of dogs with hemophilia B in the preclinical
muscle- and liver-based gene therapy studies that have pro-
gressed to human trials and discusses current research di-
rections that target these barriers.
The ability to monitor correction of the hemophilic coa-
gulopathy and the frequency of bleeding events is perhaps
the strongest reason for using dogs with hemophilia B in
preclinical studies.8–11 Also, most of the dogs that have been
used weighed 20 or more kilograms, and thus scaling up to
humans is in the range *3- to 10-fold; as opposed to mice,
which weigh *25 g, and constitute an *2800-fold scale-up.
The size of dogs places demands on manufacturing that can
slow progress if vector production is limiting. Next, dogs
provide a relevant model for identifying the challenges in-
volved with targeting gene therapy to skeletal muscle or
liver in humans. For example, transducing discrete areas of
skeletal muscle (within 0.5 cm of the injection site) or liver
in dogs is likely to be more informative of the transduction
of human tissues than the often widespread transduction in
mice. Finally, most strains of mice are inbred whereas the
available hemophilic dogs are generally outbred. Dogs thus
more faithfully model the clinical situation, where immune
responses to recombinant gene therapy vectors occur in the
context of a highly heterogeneous human population.
Canine Hemophilia B
Severe canine hemophilia B (<1% factor IX [FIX] activ-
ity or antigen) recapitulates both the genotypes and pheno-
type that occur in humans with severe human hemophilia B.
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Inheritance occurs in an X-linked manner. Like their human
counterpart, hemophilia B dogs exhibit bleeding into soft
tissues and joints that is spontaneous and severe; without
prompt treatment with FIX, the bleeds can be crippling or
fatal.10 The bleeding events are random but occur with a
measurable frequency over time. Reduction in the frequency
of annualized bleeding events can be used as a metric for
judging success of a therapeutic intervention in these dogs.11
Two hemophilia B dog models with different mutations
and immune responses to canine FIX have been used. First,
the Chapel Hill strain has a missense mutation, a G-to-A
substitution at nucleotide 1477, that results in the substitu-
tion of glutamic acid for glycine at position 379 in the
catalytic (serine protease) domain of the molecule.12 Amino
acid 379 in canine factor IX corresponds to position 381 in
human factor IX, an amino acid that has been rigorously
conserved among the trypsin-like serine proteases through-
out evolution. This mutation results in a complete lack of
circulating factor IX in the affected animals.13 This strain
only rarely makes inhibitory antibodies in response to in-
travenous administration of canine FIX. A large number of
missense mutations have been reported in human hemo-
philia B, and at least one occurs at the same location.14 This
patient has severe hemophilia B and was reported as not
making inhibitory antibodies to FIX to date.
A second strain of hemophilia B dogs that has been used
has a deletion mutation at nucleotides 772–777 and a C-to-T
transition at nucleotide 777.15 The mutation results in a
premature stop codon at amino acid residue 146, which is
just before the nucleotide sequence encoding the activation
peptide. This strain has a propensity to develop inhibitory
antibodies to canine FIX after intravenous administration of
this protein.16 Likewise, several deletion mutations have
been reported in human hemophilia B and at least one oc-
curs at the same location in association with moderate to
severe hemophilia B.17,18 The inhibitor status of humans
with the homologous deletion mutation has not been re-
ported. Immunologic challenges with canine FIX protein in
these two strains of hemophilia B dogs, however, have
shown that the risk of developing an inhibitory antibody to
FIX is substantially higher in the null mutation when com-
pared with missense mutation. Thus, the difference in in-
hibitor formation exhibited by these two models provides a
stringent strategy for addressing the immune responses to
FIX that are the major safety concern in the development of
novel strategies for treating hemophilia B.
Skeletal Muscle-Based Gene Therapy for Hemophilia B
Rationale
Skeletal muscle-based gene therapy for hemophilia B was
pursued for several reasons. First, target muscles were
chosen that were easily accessible, would limit vector bio-
distribution, and that could be removed if gene transfer re-
sulted in unanticipated adverse events. Because there was no
prior experience with parenteral administration of AAV in
humans, this latter issue was a potential concern. For-
tunately, to date, muscle removal has not been necessary.
Second, many people with hemophilia also have liver dis-
ease due to prior infections from contaminants in replace-
ment products of human origin. The safety of administering
AAV vectors to the liver in the presence of advanced liver
disease has not been established. For people with concurrent
hemophilia B and liver disease, a muscle platform is po-
tentially an attractive alternative for AAV-mediated gene
therapy. Third, posttranslational modifications of FIX
that are critical for activity, such as c-carboxylation of the
N-terminal glutamic acid residues, are supported by skeletal
myocytes.19 Two approaches for AAV-based gene transfer
to skeletal muscle have been tried in dogs and are discussed
below.
Direct intramuscular injection of AAV vectors
A series of studies have been reported in which AAV
vectors were administered by direct intraskeletal muscle
injection (Table 1).16,20–22 AAV serotypes 1, 2, and 6 have
been tested. In the hemophilia B dogs with the missense
mutation that only rarely develop inhibitors to canine FIX, a
series of findings helped identify a safe dose for the design
of the clinical trial in humans. First, AAV-1 appeared to be
associated with an increased risk of inhibitor formation to
FIX, and cyclophosphamide did not prevent the antibody
formation in the small number of animals tested.22 In con-
trast, when AAV-2 was given by intramuscular injection, a
threshold dose of up to 8.5 · 1012 vector genomes (VG)/kg
distributed over several intramuscular sites at a single sitting
appeared to be associated with transient or no inhibitor
formation.22 An especially important issue that became
evident was that increasing the dose of vector injected at a
single intramuscular site resulted in a higher frequency of
inhibitory antibodies.21 The development of AAV-1 vectors
with more robust efficacy in transducing skeletal muscle in
comparison with AAV-2 vectors did allow us to test whether
decreasing the vector dose per site would be safe and effi-
cacious. Even with reducing the vector dose per site by 5- to
20-fold, however, inhibitory antibodies to FIX were still
detected. By comparison, in the hemophilia B dogs with the
deletion mutation, neutralizing anti-FIX antibodies devel-
oped with intramuscular injection of the same AAV-2 vector
at a dose of 1 · 1012 VG/kg.16 Thus, with the intramuscular
injections, the risk of forming anti-FIX inhibitory antibodies
is influenced by the AAV serotype, the dose of vector and
especially the dose per site, as well as the underlying mu-
tation. The role of the serotype likely relates to the amount
of FIX produced locally, whereas the role of the causative
mutation relates to the degree of tolerance to FIX.
Although this compendium of information provided criti-
cal safety data needed for designing the clinical trials that
used a muscle platform in humans as discussed below, it
also became clear that the number of intramuscular injec-
tions needed to administer a therapeutic vector dose was too
high to be practical clinically. Thus, different methods were
needed for delivering therapeutic doses of AAV vector to
skeletal muscle. Because skeletal muscle exhibits one of
the highest densities of capillaries in the body, the use of
intravascular delivery was considered an attractive alter-
native strategy for achieving a widespread area of muscle
transduction.
Isolated limb perfusion and afferent transvenular
retrograde extravasation
Two intravascular approaches for transduction of large
amounts of skeletal muscle have been pursued in hemophilia
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B dogs. First, using an approach initially developed for de-
livering chemotherapy to an isolated limb in humans23–25 and
gene therapy of large muscle groups in animal models of
muscular dystrophy,26 isolated limb perfusion (ILP) was
performed by surgically isolating and cannulating the femoral
artery and vein while a tourniquet was applied proximally.27
Transient (6 weeks) immunomodulation with cyclophospha-
mide was given concurrently to prevent the development of
anti-FIX antibodies. Notably, long-term ( > 3 years) FIX ex-
pression with circulating levels of 4–15% was achieved (Ta-
ble 1). These levels were substantially higher than what was
observed with intravenous infusion of the same vector but
without the ILP procedure. Omission of immune suppression
was accompanied by inhibitory anti-FIX antibody formation.
Immunohistochemistry of muscle biopsies confirmed that FIX
expression was present in several muscle groups from the
treated limb. This ILP procedure included administering pa-
paverine for vasodilation and histamine to increase vascular
permeability.26 Because histamine is not currently Food and
Drug Administration (FDA)-approved for use in humans and
has proinflammatory effects, this procedure needed modifi-
cation before translation to humans. These data, however, did
provide proof-of-concept supporting the rationale for intra-
vascular delivery of AAV vectors to skeletal muscle.
The second approach, afferent transvenular retrograde ex-
travasation (ATVRX), is much simpler to perform. A tour-
niquet is applied at the hip to occlude blood flow and isolate
the hind limb. Using a distal vein for access, the AAV vector
is infused intravenously under pressure to increase vascular
permeability.28–30 As in the ILP approach, transient (6 weeks)
immunomodulation with cyclophosphamide was also given to
prevent the development of anti-FIX antibodies. Importantly,
this approach produced widespread transduction of muscle
and sustained, dose-dependent therapeutic levels of canine
FIX up to 10-fold higher than those obtained by direct intra-
muscular injections. Although all animals developed a robust
humoral antibody response to the AAV capsid, no T cell re-
sponses to the capsid antigen were detected by interferon
(IFN)-c enzyme-linked immunosorbent spot (ELISPOT).29
Preliminary studies on interleukin (IL)-10 ELISPOT screening
of lymphocytes showed reactivity to canine FIX-derived
peptides, and restimulation of T cells in vitro in the presence
of the identified canine FIX epitopes resulted in the expansion
of CD4 + FoxP3 + IL-10+ T cells. It is possible that these
T cells may have suppressor activity and may contribute to
modulation of the immune responses to the transgene product
in AAV-mediated gene transfer, but additional studies are
needed to confirm this idea.
The accumulating data on gene therapy for hemophilia B
strongly suggest that lower AAV vector doses are less
likely to induce an immune response regardless of the target
organ.4–6 The ATVRX procedure has also been used with a
strategy to reduce vector dose while still expressing a thera-
peutic level of FIX, using the gain-of-function mutation
FIX-R338L (Padua) that exhibits an 8- to 9-fold increase in
specific activity of FIX.31 To date, three hemophilia B dogs
have received an AAV-6 vector containing canine FIX-R338L
along with transient cyclophosphamide immunomodulation
(Table 1). Neither anti-FIX antibodies nor T cell responses
to FIX-R338L have been detected using a dose range of 2.6–
3 · 1012 VG/kg. Remarkably, the net level of FIX activity
(3.5–8%) is 8- to 9-fold higher in specific activity, as was
originally found in humans who inherited this gain-of-function
mutation.32 These dogs have not had any detectible throm-
botic complications and have enjoyed a marked reduction
in the frequency of bleeding events.
Several findings in these muscle-based recombinant AAV
gene therapy studies deserve comment. First, multiple assays
have been developed that provide a comprehensive assess-
ment of the T and B cell-mediated immune responses to re-
combinant AAV vectors and the expressed FIX in dogs.21,28,29
Second, transient immune modulation has been associated
with circumventing immune responses that would otherwise
limit the success of AAV-mediated gene transfer. Third,
efficient muscle transduction can be achieved with the
ATVRX procedure in hemophilia B dogs naive to recom-
binant AAV vectors and by using alternative AAV serotypes
in hemophilia B dogs with high titers of neutralizing anti-
AAV-2 antibodies from prior exposure in earlier gene
transfer studies (Table 1).28,29 At present, it is estimated that
more than 40% of people with hemophilia B being screened
as potential gene therapy candidates will be excluded on the
basis of the presence of neutralizing antibodies to AAV-2 or
other serotypes brought about by prior exposure to wild-
type virus earlier in life. Delivery through an ATVRX
procedure, in which the closed circulation is first flushed
with normal saline, may make it possible to use skeletal
muscle even in those subjects with neutralizing antibodies
(although this has not yet been demonstrated experimen-
tally). Fourth, canine FIX can be modified to recapitulate
the human R338L gain-of-function mutation to help develop
strategies for avoiding immune responses to AAV vectors
by lowering the dose required for therapeutic expression.
Muscle-based gene therapy for human hemophilia B
To date, one muscle-based clinical trial has been conducted
in hemophilia B and the AAV vector was administered by
direct intramuscular injections (Table 1). This was the first
trial of intramuscular injection of an AAV vector for any
disease. This phase 1 safety study used the same AAV-2
CMV-FIX vector that had been tested in the hemophilia B
dogs except that the transgene was human rather than ca-
nine.1–3 Guided by the results in the hemophilia B dogs, pa-
tients with missense mutations were selected for study. As
expected, based on the preclinical studies in dogs and other
species (not discussed), expression levels were low ( < 1% to
1%) but no serious adverse events have been reported with
follow-ups ranging up to 4 years. Three important findings
from the human study that were presaged by the preclinical
studies in hemophilia B dogs were as follows: (1) intramus-
cular injection of AAV-FIX at doses up to 2 · 1012 VG/kg in
humans was safe, with no evidence of formation of inhibitory
antibodies to FIX or other toxicities; (2) the characteristics of
skeletal muscle transduction by AAV-2 were similar in hu-
mans, dogs, and mice; and (3) local transgene expression
appeared stable over a period of up to 10 years after vector
injection.3,33 As discussed previously, the number of intra-
muscular injections required for this approach to achieve
clinically therapeutic levels of FIX will likely preclude further
development of the direct intramuscular injection approach at
this time. It is reasonable to suggest that the ATVRX proce-
dure combined with the FIX-R338L gain-of-function variant
or alternate serotypes of AAV vectors would be acceptable for
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muscle-based gene transfer for hemophilia B subjects with
severe underlying liver disease or high titers of neutralizing to
recombinant AAV capsid antigens that would exclude them
from being enrolled in liver-based gene therapy.
Liver-Based Gene Therapy for Hemophilia B
Rationale
Because FIX is normally produced in hepatocytes, the
liver is a natural target for gene therapy of hemophilia B.
AAV vectors with a natural tropism for the liver, inclusion of
liver-specific promoters in expression cassettes, and multiple
routes of administration have been used to drive expression
of therapeutic levels of FIX. Another benefit of targeting the
liver is that immune tolerance to antigens expressed from an
AAV vector in the liver has been well documented.34,35 This
immune tolerance is due, at least in part, to the induction
of antigen-specific regulatory T cells.36,37 Such a scenario
would be expected to decrease the likelihood of the forma-
tion of anti-FIX antibodies after liver-based gene therapy. As
discussed below, an unexpected T cell-mediated immune
response to recombinant AAV vector capsid proteins oc-
curred in humans after liver-based gene therapy. Although
this event initially threatened the success of gene transfer,
fortunately, a short course of prednisolone, administered
with appropriate timing, was associated with interruption of
this immune response and preservation of FIX expression.
Portal and peripheral vein administration
of AAV vectors for canine hemophilia B
Both the portal vein and peripheral vein routes of ad-
ministration have been reported in hemophilia B dogs, using
AAV vectors made from serotypes 2, 5, and 8 (Table 2).38–42
Both strains of hemophilia B dogs were included and in all
cases expression of FIX was detected. Only one dog ex-
hibited transient anti-FIX antibodies, and this specific he-
mophilia B dog (Beech) had the null mutation in the FIX
gene described previously, another genetic mutation resulting
in pyruvate kinase deficiency that is associated with iron
overload in the liver, and anti-phospholipid antibodies.40
Also, in a separate study, dogs that previously had been
given AAV-2 vectors by portal vein were subsequently gi-
ven pseudotyped AAV-2/8 by repeat portal vein adminis-
tration, and these retreated dogs exhibited higher levels of
FIX expression (Table 2).41 This finding raises the possi-
bility that some human subjects may achieve higher levels
of circulating FIX with repeat liver-based gene therapy us-
ing different serotypes of AAV or modifications of the AAV
capsid proteins.
Liver-based gene therapy for human hemophilia B
The preclinical information in dogs suggested that the
humoral immune response to FIX in liver-based gene ther-
apy for hemophilia B would be acceptable for both missense
and deletion mutations, and this has been the case so far in
human subjects who have been infused with AAV vectors.
In the first study, administration of the AAV-2 vector via the
hepatic artery was well tolerated and expression levels were
initially in a therapeutic range (Table 2).4 The vector dose
response that had been detected in hemophilia B dogs with
liver-based gene therapy was also initially seen in these
subjects. Unexpectedly, FIX expression declined to baseline
over *8 weeks, and was accompanied by a reversible and
asymptomatic elevation in liver transaminases.4 Over time,
detailed investigations generated evidence to support the
hypothesis that the transduced hepatocytes had been de-
stroyed by a CD8 + T cell-mediated immune response that
targeted antigens of the AAV capsid.43 Thus, this study
showed that recombinant AAV-2 vectors could successfully
transduce human hepatocytes in vivo as had been shown in
other species, but that a modification of the protocol was
necessary to achieve long-lasting expression in humans.
Armed with this information, a self-complementary AAV-8
vector was given via a peripheral vein to humans with he-
mophilia B5,6 with a broader range of molecular defects than
were included in the first liver-based trial (Table 2). With
doses below 2.0 · 1012 VG/kg, the subjects exhibited stable
expression of FIX in the range of 1.4–2.86% of normal FIX
activity. With doses at or above 2.0 · 1012 VG/kg, four of
six subjects developed elevations in liver transaminases and
a reduction in FIX expression. Short-term administration of
prednisolone was associated with interruption of the capsid-
specific T cell response and prevention of further loss of
FIX expression. Despite this need for immunomodulation at
higher doses in these four subjects, persistent, long-term
expression of FIX has now been documented. As in the first
liver-based trial, no study subjects have developed inhibi-
tory antibodies to FIX to date. The ranges of FIX expression
levels are consistent with conversion of the hemophilia B
phenotype from severe to mild or moderate. Indeed, this
has been the case because most of these subjects have either
reduced their dependence on prophylactic FIX infusions
or stopped prophylaxis altogether. Spontaneous bleeding
events have been infrequent to rare and, when they have
occurred, bleeding has been easily managed with standard
FIX replacement therapy. The follow-up in this liver-based
trial is relatively short (*3 years), but the sustained ex-
pression of FIX that has been observed for > 10 years in
many hemophilia B dogs provides an encouraging outlook
for a much longer period of benefit.
Discussion
The results of preclinical gene therapy studies in dogs
with hemophilia B have helped investigators design safe and
efficacious AAV-mediated gene therapy trials in people
with hemophilia B. To date, the formation of inhibitory
antibodies to FIX has been circumvented in both muscle-
and liver-based human trials at least in part by using the
results obtained from studies in dogs. Also, results showing
long-term (years) expression of FIX from both muscle and
liver have been successfully translated from dogs to humans.
The reduction in frequency of bleeding events and use of
factor IX products enjoyed by the successfully treated dogs
has also been translated to the participants in the second
liver-based trial. This improvement in bleeding phenotype
was a secondary outcome of study design in humans but of
primary importance to the field of gene therapy.
The T cell-mediated immune response to the AAV vector
that occurred in the liver-based trials, however, was not
predicted in preclinical studies in any species. The reasons
for this apparent species-specific immune response to re-
combinant AAV gene therapy vectors for hemophilia B are




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































not completely understood. In humans, wild-type AAV in-
fection is not associated with a recognized disease syndrome
but seroepidemiology studies have suggested influence on
reproductive outcomes.44 In contrast, parvoviral infections
in dogs are associated with a high mortality rate ( > 90%)
and the disease is extremely contagious and can be devas-
tating in a colony setting.45 Because of the dangerous nature
of the canine parvoviral infection, most puppies are immu-
nized between 4 and 6 weeks of age to prevent disease. Both
canine parvovirus and AAV are members of the Parvovir-
idae family and share sequence identity.46 Thus, it is pos-
sible that the immune response to canine parvoviral
vaccination in puppies could influence recombinant AAV-
mediated gene therapy in adult dogs.47 The canine immune
responses to recombinant AAV vectors have limited trans-
gene expression in canine a1-antitrypsin deficiency.
48 Also,
a dog model of Duchenne muscular dystrophy showed an
AAV capsid-mediated response and clearance of most but
not all transduced cells over time.49 Long-term expression,
however, was achieved by short-term administration of anti-
thymocyte globulin, cyclosporine, and mycophenolate mo-
fetil.50 At present, the essential practice of canine parvoviral
immunization is a common denominator in these studies.
How this vaccination program in puppies with developing
immune systems influences the immune response to non-
replicating recombinant AAV vectors of different serotypes
in different disease processes in dogs with mature immune
systems remains an ongoing area of investigation.7,51
The current level of success of gene therapy for hemophilia
raises the question of how reimbursement will be structured
for the gene therapy vectors that are approved and become
licensed for clinical use.52–54 This important issue will require
considerable discussion, debate, and planning. Traditionally,
medications are paid for when they are received. This ap-
proach has generally been accepted for treatment for rare
diseases such as hemophilia, with the understanding that the
cost, as with all new medications, is in part paying for the
research required for safe and effective drug development.
This approach has been less acceptable with new medications
that, although highly effective,55 target very large popula-
tions of affected patients. For example, the projected cost
for treating the more than 3 million patients with hepatitis
C in the United States with recently approved medications
is *$85,000 per patient.56 In comparison, it is estimated that
there are *200 patients with lipoprotein lipase deficiency
(LDLD) in Europe who would potentially be candidates for
Glybera (alipogene tiparvovec), the first gene therapy drug to
be approved. Glybera is anticipated to cost $1.4 million dol-
lars.57 Because the anticipated cure rates are high with these
respective treatments for hepatitis C and LDLD, it is imper-
ative to identify mechanisms for payment. An alternative
payment plan that has been suggested for medications that are
anticipated to have a high cost is to consider an annuity ap-
proach that would provide reimbursement on an annual basis
if preagreed-on goals for successful treatment are achieved
from year to year. To evaluate the potential feasibility and
acceptability of such an approach, it will be essential to have
preclinical data that reliably predict continued therapeutic
success over such a time frame. Preclinical testing of gene
therapy vectors in dogs with hemophilia B has accurately
predicted successful long-term ( > 10 years) expression of FIX
(K.A.H., V.R.A., H.H.S., M.A.K., and T.C.N., unpublished
follow-up data on the dogs listed in Tables 1 and 2).58 These
preclinical data on long-term expression will likely become
increasingly important in the discussions of how reimburse-
ment for these new and highly effective medications will
occur.
Another aspect of product development in which hemo-
philic dogs have proven valuable is observation for long-
term or late side effects, especially for insertional muta-
genesis events. Such events occurred with integrating vec-
tors used for the X-linked SCID trials,59 and the first cases
of insertional mutagenesis leading to leukemia were re-
ported 3 years after vector transduction. This is a delayed
complication that could not be readily observed in mouse
models where life expectancy is closer to 18 months. Data
from a number of investigators have established that AAV
vectors, although predominantly nonintegrating, do inte-
grate at sites throughout the genome when administered at
doses used in ongoing clinical studies.60–62 The absence of
hepatocellular carcinoma in dogs that have received relevant
doses of recombinant AAV vectors and were subsequently
surveyed for as long as a decade or more is thus reassuring
in this respect.
As a result of the successful translation of gene therapy
for hemophilia B from preclinical animal models to humans,
at least three other groups are initiating AAV vector-based
trials for hemophilia B including the FIX-R338L (Padua)
discussed previously.7,63 Also, attention is now being re-
directed to gene therapy for hemophilia A.64 The number of
available or eligible subjects with hemophilia A and he-
mophilia B may become a barrier to successful enrollment
in a large number of trials. To meet these demands, both the
hemophilia A65,66 and hemophilia B dogs will continue to
provide excellent models to test new gene therapy ap-
proaches for these rare bleeding disorders.67
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